A Phase 1 interventional study of Molnupiravir in Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 27th largest by enrollment, is one of 2 that started in 2022, is one of 25 in phase 1, and was the 26th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.
Browse Renal Insufficiency studies →2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 18–80 · Healthy volunteers
Merck Sharp & Dohme LLC
Ages 18–80 · Healthy volunteers
By country, each count listing its studies:
Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 1,061 interventional studies indexed under Renal Insufficiency.
Median enrollment 26 across the 32 interventional studies. Of the 29 that completed or were terminated, 17 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
2 of the studies in Renal Insufficiency by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07734610Merck Sharp & Dohme LLCA Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027) | 2027-02-01 |
| NCT07922174Merck Sharp & Dohme LLCA Clinical Trial of MK-6916 in Participants With Moderate and Severe Kidney Disease Compared to Healthy Controls (MK-6916-013) | 2027-08-06 |
Add all 2 to your calendar (.ics) → With an account.
Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to evaluate the plasma pharmacokinetics (PK) of N-hydroxycytidine (NHC), the nucleoside metabolite of molnupiravir, after a single oral dose of 800 mg molnupiravir in participants with severe renal impairment compared to healthy mean matched control participants. This study will also assess the safety and tolerability of molnupiravir in participants with severe renal impairment and the urinary excretion of NHC after a single oral dose of 800 mg molnupiravir in participants with severe renal impairment compared to healthy mean matched control participants. The primary hypothesis is that the plasma PK participants with severe renal impairment will be similar to that observed in the healthy mean matched control participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The key Inclusion Criteria include but are not limited to the following:
Exclusion Criteria:
The key Exclusion Criteria include but are not limited to the following:
Severe renal impairment participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with severe renal impairment will receive a single oral 800 mg dose of molnupiravir.
Drug: Molnupiravir
Participants in the healthy mean matched control group will receive a single oral 800 mg dose of molnupiravir.
Drug: Molnupiravir
Four 200 mg capsules administered orally as a single dose
Also known as: MK-4482; MOV; EIDD-2801
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)
Blood for plasma samples was collected at pre-specified time points to determine the AUC0-inf of NHC.
Time frame: Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose
Maximum Plasma Concentration (Cmax) of NHC
Blood for plasma samples was collected at pre-specified time points to determine the Cmax of NHC.
Time frame: Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose
Number of Participants Who Experienced an Adverse Event (AE)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
Time frame: Up to Day 15
Amount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC)
Urine was collected at pre-specified time points to determine the amount of dose Administered excreted in urine (Ae) of NHC.
Time frame: Predose, 4, 8, 12 and 24 hours postdose
Fraction of the Dose Administered Excreted in Urine (Fe) of NHC
Urine was collected at pre-specified time points to determine the Fraction of the dose administered excreted in urine (Fe) of NHC.
Time frame: Predose, 4, 8, 12 and 24 hours postdose
Renal Clearance (CLr) of NHC
Urine will be collected at pre-specified time points to determine the Renal Clearance (CLr) of NHC
Time frame: Predose, 4, 8, 12 and 24 hours postdose
| Milestone | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Blood for plasma samples was collected at pre-specified time points to determine the AUC0-inf of NHC.
| hr*ng/mL | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC) | 11100 (7990 to 15400) | 8960 (7660 to 10500) |
Blood for plasma samples was collected at pre-specified time points to determine the Cmax of NHC.
| ng/mL | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Maximum Plasma Concentration (Cmax) of NHC | 3920 (2810 to 5460) | 3240 (2630 to 4000) |
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.
| Participants | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Number of Participants Who Experienced an Adverse Event (AE) | 2 | 0 |
Urine was collected at pre-specified time points to determine the amount of dose Administered excreted in urine (Ae) of NHC.
| mg | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Amount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC) | 3.72 ± 50.9 | 14.6 ± 172 |
Urine was collected at pre-specified time points to determine the Fraction of the dose administered excreted in urine (Fe) of NHC.
| % of administered dose | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Fraction of the Dose Administered Excreted in Urine (Fe) of NHC | 0.591 ± 50.9 | 2.33 ± 172 |
Urine will be collected at pre-specified time points to determine the Renal Clearance (CLr) of NHC
| L/hr | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| Renal Clearance (CLr) of NHC | 0.338 ± 62.1 | 1.64 ± 162 |
Collected over Up to ~ Day 15. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Participants With Severe Renal Impairment | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Healthy Participants With Normal Renal Function | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Event | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function |
|---|---|---|
| ConstipationGastrointestinal disorders | 1/8 | 0/8 |
| HyperkalaemiaMetabolism and nutrition disorders | 1/8 | 0/8 |
| Age, Continuous(Years) | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function | Total |
|---|---|---|---|
| Mean | 63.5 ± 7.9 | 59.6 ± 2.0 | 61.6 ± 5.9 |
| Sex: Female, Male(Participants) | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function | Total |
|---|---|---|---|
| Female | 0 | 1 | 1 |
| Male | 8 | 7 | 15 |
| Ethnicity (NIH/OMB)(Participants) | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 4 | 8 |
| Not Hispanic or Latino | 4 | 4 | 8 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Participants With Severe Renal Impairment | Healthy Participants With Normal Renal Function | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 3 | 5 |
| White | 6 | 5 | 11 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Jun 2022 to primary completion in Feb 2023, 7 months.
Results were first posted in Jul 2024, 1 year 5 months after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Molnupiravir